What is Vivoo?
Vivoo operates at the intersection of digital health and personalized medicine, offering a suite of at-home testing solutions that empower users to monitor critical health metrics. By utilizing proprietary urine analysis technology, the company provides real-time data on hydration, vaginal pH, and fertility, among other wellness indicators. This data-driven approach allows users to receive personalized expert advice directly through the Vivoo application, effectively democratizing access to health diagnostics. The company's market position is defined by its focus on health-conscious individuals, particularly women, who require convenient, reliable, and actionable health data to manage their well-being proactively. By streamlining the testing process, Vivoo has successfully reduced the friction typically associated with traditional laboratory diagnostics.
How much funding has Vivoo raised?
Vivoo has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2021): $6M with participation from Revo Capital, Global Ventures, ONCE Ventures, Halogen Ventures, 500 Global, and Draper Associates
Key Investors in Vivoo
Revo Capital
Revo Capital is a venture capital firm that invests in innovative, early-stage B2B and B2C technology ventures primarily in Turkey, Eastern Europe, and the Baltics.
Halogen Ventures
Halogen Ventures is an early stage venture capital fund that invests in consumer technology companies led by women, providing strategic guidance to help them grow.
Draper Associates
Draper Associates is a global venture capital firm with over 40 years of experience in funding transformative companies across various sectors, including AI, blockchain, and biotech.
What's next for Vivoo?
With this major strategic investment, Vivoo is poised to scale its operations and enhance its diagnostic capabilities. The company's roadmap likely includes the expansion of its product portfolio to cover a wider array of health parameters, alongside potential partnerships with healthcare providers to integrate its data into broader clinical workflows. As the firm transitions from its current growth phase toward a more mature enterprise-level operation, the focus will remain on refining its AI-driven insights and expanding its global footprint. The backing from high-profile venture capital firms provides not only the necessary financial runway but also the strategic guidance required to navigate the complexities of the global health-tech landscape, ensuring that Vivoo remains at the forefront of the personalized wellness revolution.
See full Vivoo company page
